New insider Cavanagh Bethany J claimed ownership of 42,720 shares (SEC Form 3)
$BEAM
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 08/09/2024 |
3. Issuer Name and Ticker or Trading Symbol
Beam Therapeutics Inc. [ BEAM ] |
|||||||||||||
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Common Stock | 42,720(1)(2) | D | |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Stock Option (Right to Buy) | (3) | 03/31/2031 | Common Stock | 8,542(4) | $80.04 | D | |
| Stock Option (Right to Buy) | (5) | 08/31/2031 | Common Stock | 7,500 | $110.92 | D | |
| Stock Option (Right to Buy) | (6) | 01/31/2032 | Common Stock | 20,000 | $69.21 | D | |
| Stock Option (Right to Buy) | (7) | 01/31/2033 | Common Stock | 27,000 | $43.45 | D | |
| Stock Option (Right to Buy) | (8) | 01/31/2034 | Common Stock | 20,000 | $24.4 | D | |
| Explanation of Responses: |
| 1. Includes 1,250, 1,875, 5,000, 10,125, 9,500 and 10,000 restricted stock units ("RSUs") granted to the Reporting Person under the Issuer's 2019 Equity Incentive Plan on March 31, 2021, September 30, 2021, March 31, 2022, March 31, 2023, December 31, 2023, and March, 31, 2024, respectively. |
| 2. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The March 31, 2021, September 30, 2021, March 31, 2022, March 31, 2023 and March 31, 2024 RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with the Issuer through each vesting date. The December 31, 2023 RSUs grant vests on the one-year anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through the vesting date. The March 31, 2021 RSUs grant was originally for 5,000 RSUs of which 3,750 have already vested. The September 30, 2021 RSUs grant was originally for 3,750 RSUs of which 1,875 RSUs have already vested. The March 31, 2022 RSUs grant was originally for 10,000 RSUs of which 5,000 RSUs have already vested. The March 31, 2023 RSUs grant was originally for 13,500 RSUs of which 3,375 RSUs have already vested. |
| 3. The option vests at a rate of 2.08% each month after March 31, 2021 until the option is fully vested. |
| 4. The option grant was originally for options to purchase 10,000 shares of the Issuer's common stock of which 1,458 have already been exercised. |
| 5. The option vests at a rate of 2.08% each month after August 31, 2021 until the option is fully vested. |
| 6. The option vests at a rate of 2.08% each month after January 31, 2022 until the option is fully vested. |
| 7. The option vests at a rate of 2.08% each month after January 31, 2023 until the option is fully vested. |
| 8. The option vests at a rate of 2.08% each month after January 31, 2024 until the option is fully vested. |
| Remarks: |
| Exhibit List: Exhibit 24 - Power of Attorney |
| By: /s/ Christine Bellon, Attorney-in-Fact | 08/19/2024 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||